EGFR and breast cancer: Postmenopausal women at elevated risk of BC may benefit from a five-year regimen of 60 mg/day.34 In mouse models of triple-negative breast cancer (TNBC), a daily oral dose of RLX inhibited tumor growth, promoted regression, reduced epidermal growth factor receptor (EGFR) expression, and diminished tumorigenicity in human TNBC cells.35 Furthermore, the combination of RLX and naringin increased antioxidant activity, suggesting that co-delivery via nanostructured lipid carriers could enhance therapeutic effectiveness and reduce side effects.35